Clinical Trials Browser

Interventional × tazemetostat × 1 year × Clear all

NCT03348631 2026-03-18

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Phase 2 Active not recruiting

62 enrolled 14 charts

Ovarian Neoplasms

NCT03854474 2026-03-18

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04557956 2026-03-18

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Phase 1/2 Active not recruiting

Melanoma

NCT05353439 2026-03-18

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT05627245 2026-03-18

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1 Active not recruiting

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT04705818 2026-03-06

CAIRE

Phase 2 Completed

GastrointestinalSarcoma

Tertiary Lymphoid Structures, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04224493 2026-03-02

SYMPHONY-1

Phase 3 Recruiting

Lymphoma, Follicular

NCT05551936 2026-02-17

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT07407283 2026-02-12

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT03155620 2026-02-10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT04917042 2026-02-04

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

Phase 2 Active not recruiting

10 enrolled 12 charts

Inhibition, Psychological, Sarcoma, Nerve Sheath Neoplasms, Neurofibrosarcoma

NCT06068881 2026-01-30

Mandolin

Phase 2 Withdrawn

Lymphoma, Follicular

NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2 Suspended

Lymphoma, Follicular

NCT06242834 2026-01-14

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06692452 2026-01-07

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT06824701 2025-12-03

TARZAN

Phase 1 Recruiting

Recurrence, Lymphoma, B-Cell

NCT02875548 2025-11-04

TRuST

Phase 1/2 Completed

LymphoidOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT05407441 2025-10-03

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Phase 1/2 Recruiting

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05983965 2025-09-10

Study of Tazemetostat in Lymphoid Malignancies

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, T-Cell

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT05934838 2025-08-15

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Phase 1 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02601950 2025-06-22

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Phase 2 Completed

267 enrolled 25 charts 2 FDA

Sarcoma, Sarcoma, Synovial

NCT04846478 2025-04-17

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05994235 2025-04-09

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT05618366 2025-04-08

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse